SSTR2 and Hypoglycemia: In the current study, the increased time before hypoglycemia onset, and the decreased incidence of hypoglycemia following SSTR2 antagonist treatment (PRL-2903, Figure 4B) was accompanied by a corresponding increase in plasma glucagon level and a decrease in liver glycogen content (Figure 4F, p = 0.08).